MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...
Just take a look at the healthcare sector. By all accounts, healthcare stocks should be in the dumps. The sector sold off ...
11h
Hosted on MSNPET Imaging Falls Flat for Initial Liver Cancer StagingPET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans in only a tiny ...
William Blair analysts have lowered their FY2027 earnings per share estimate for Bristol-Myers Squibb from $7.70 to $6.50.
This was the stock's fifth consecutive day of gains.
Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...
In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...
The application was based on results from the three-arm Phase 3 CheckMate -8HW study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results